← Back to Clinical Trials
Recruiting NCT06653998

NCT06653998 Feasibility and Safety of Early Mobilization and Rehabilitation in Intensive Care Unit Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06653998
Status Recruiting
Phase
Sponsor Claudia Aristizábal
Condition Intensive Care Unit Acquired Weakness
Study Type OBSERVATIONAL
Enrollment 220 participants
Start Date 2024-05-10
Primary Completion 2025-03

Trial Parameters

Condition Intensive Care Unit Acquired Weakness
Sponsor Claudia Aristizábal
Study Type OBSERVATIONAL
Phase N/A
Enrollment 220
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-05-10
Completion 2025-03
Interventions
Early mobilization and rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Intensive Care Unit Acquired Weakness (ICU-AW) is a common complication of critical illnesses, occurring in approximately 50% of ICU patients and is strongly associated with increased morbidity, physical impairments, and both short- and long-term mortality. The main characteristics of ICU-AW are symmetrical generalised muscle weakness affecting both respiratory and limb muscles; however, the clinical phenotype may differ depending on age, disease burden, length of ICU stay, and mechanical ventilation duration. The objective of the present study is to evaluate the feasibility achieved and the safety outcomes reported in a cohort of critically ill patients who undergo early mobilisation and rehabilitation in intensive care units. This research is a multicentre prospective cohort study.

Eligibility Criteria

Inclusion Criteria: * Patients ≥ 18 years of age admitted to the intensive care units. Exclusion Criteria: * Patients requiring extracorporeal membrane oxygenation (ECMO). * Patients without indication for early mobilisation in the ICU (severe hemodynamic instability, acute brain or spinal injury with rest orders, anaemia (Hb \<8 mg/dl), thrombocytopenia (platelets \<50,000), active systemic inflammatory response according to institutional protocols). * Patients in the postoperative period of cardiac transplantation.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology